FDA Approves Auto-Injector for Migraine, Cluster Headache

FDA Approves Auto-Injector for Migraine, Cluster Headache

(MedPage Today) -- The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and cluster headaches in adults, Amneal Pharmaceuticals announced Thursday. The prefilled syringe formulation...

FDA Approves First Autoinjector Form of DHE for Acute Migraine and Cluster Headache

Markted as Brekiya, Amneal Pharmaceuticals’ newly approved therapy offers a self-administered version of dihydroergotamine mesylate for adults with migraine or cluster headache.

FDA Approves Dihydroergotamine as Auto Injectable for Migraine Treatment

Dihydroergotamine (Brekiya) is an acute treatment to help relieve migraine attacks, and it can come in nasal sprays, injections, and intravenous infusions.

FDA approves Amneal’s DHE autoinjector for migraine

The US Food and Drug Administration has granted approval to Amneal Pharmaceuticals’ Brekiya (dihydroergotamine (DHE) mesylate) autoinjector.

Amneal gets U.S. FDA approval for Brekiya injection for the acute treatment of migraines

BRIDGEWATER, N.J. – Amneal Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya (dihydroergotamine mesylate) injection, the first and only dihydroergotamine (DHE) autoinjector for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.Brekiya autoinjector provides patients with the potential for sustained pain relief† in a convenient, self-a…

FDA Approves Brekiya, First and Only DHE Autoinjector, for Acute Treatment of Migraine, Cluster Headaches

The approved injection contains dihydroergotamine (DHE), which is the same medication used in hospitals, in a ready-to-use device.